Lansoprazole oro-dispersible tablet: Pharmacokinetics and therapeutic use in acid-related disorders

Drugs

Volumn 65, Issue 10, 2005, Pages 1419-1426

  Baldi, Fabio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; WATER;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DELAYED RELEASE FORMULATION; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; HUMAN; NASOGASTRIC TUBE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHYSICIAN; REVIEW; STOMACH EMPTYING; STOMACH PH; TABLET; TABLET FORMULATION; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; GASTROESOPHAGEAL REFLUX; HUMANS; OMEPRAZOLE; PROTON PUMPS; TABLETS; TECHNOLOGY, PHARMACEUTICAL; TREATMENT OUTCOME;

EID: 22944453085     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565100-00007     Document Type: Review

References (33)

1. Levin TR, Schmittdiel JA, Kunz K, et al. Costs of acid-related disorders to a health maintenance organization. Am J Med 1997; 103: 520-8
2. Scott M, Gelhot AR. Gastroesophageal reflux disease: diagnosis and management. Am Fam Physician 1999; 59: 1161-9, 1199
3. Locke III GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56
4. Tolman KG, Sanders SW, Buchi KN, et al. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997; 24: 65-70
5. Fitton A, Wiseman L. Pantoprazole: a review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51 (3): 460-82
6. Hassan-Alin M, Andersson T, Bredberg E, et al. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000; 56: 665-70
7. Swan SK, Hoyumpa AM, Merritt GJ. Review article: the pharmacokinetics of rabeprazole in health and disease. Aliment Pharmacol Ther 1999; 13 Suppl. 3: 11-7
8. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet 1991; 20 (1): 38-49
9. Stedman CAM, Barclay ML. Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963-78
10. Matheson AJ, Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorders. Drugs 2001; 61 (12): 1801-33
11. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active-and placebo-controlled study of misoprostol vs lansoprazole. NSAID-Associated Gastric Ulcer Prevention Study Group. Arch Intern Med 2002; 162 (2): 169-75
12. Misiewicz JJ, Harris AW, Bardhan KD, et al. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut 1997; 41 (6): 735-9
13. Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician 2002; 66 (2): 273-80
14. Scott LJ, Dunn CJ, Mallarkey G, et al. Esomeprazole: a review of its use in the management of acid-related disorders in the US [published erratum appears in Drugs 2002; 62 (15): 2183]. Drugs 2002; 62 (7): 1091-118
15. Tateno M, Nakamura N. Phase I study of lansoprazole antiulcer agent: capsule form. J Clin Ther Med 1991; 7: 51-62
16. Tabata T, Kashihara T, Hirai S, et al. Effect of gastric pH on the absorption of a new antiulcer drug (lansoprazole) in the beagle dog. J Biopharm Sci 1991; 2: 319-28
17. Baldi F, Malfertheiner P. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. Digestion 2003; 67: 1-5
18. Freston JW, Chiu YL, Mulford DJ, et al. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment Pharmacol Ther 2003; 17: 361-7
19. Gremse DA, Donnelly JR, Kukulka MJ, et al. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe. Aliment Pharmacol Ther 2004; 19: 1211-5
20. Taubel J, Lorch U, Baxter G. A comparison of the bioavailability of 15mg lansoprazole oro-dispersible tablet dispersed in the mouth with prior dispersal in water [abstract]. Gut 2003; 52 Suppl. 6: A61
21. Freston JW, Kukulka MJ, Lloyd E, et al. A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube. Aliment Pharmacol Ther 2004; 20: 407-11
22. Gerloff J, Mignot A, Barth H, et al. Pharmacokinetics and absolute bioavailability of lansoprazole. Eur J Clin Pharmacol 1996; 50: 293-7
23. Iwasaki K, Yoshikawa Y, Shibata N, et al. Evaluation of fast disintegrating lansoprazole tablet in human subjects. Drug Metab Pharmacokinet 2004; 19: 227-35
24. Pumfrey B, Baxter G. Patient administration and acceptability of the lansoprazole oro-dispersible tablet [abstract]. Gut 2004; 53 Suppl. 6: A289
25. Morelli P, Gambardella F, Tuccillo M, et al. Lansoprazole orally disintegrating tablets (LODT): an Italian study of awareness, use and satisfaction of this new formulation among physicians [abstract]. Digest Liver Dis 2005; 37 Suppl. 1: S81
26. Baldi F, Cavoli C, Ghersi S, et al. A comparison of the new lansoprazole orally disintegrating tablets (LODT) with esomeprazole in patients with non erosive reflux disease [abagent: stract]. Digestive Disease Week; 2005 May 14-19; Chicago
27. Sanders SW, Tolman KG, Greski PA, et al. The effects of lansoprazole, a new H+,K(+)-ATPase inhibitor, on gastric pH and serum gastrin. Aliment Pharmacol Ther 1992; 6: 359-72
28. Hongo M, Ohara S, Hirasawa Y, et al. Effect of lansoprazole on intragastric pH: comparison between morning and evening dosing. Dig Dis Sci 1992; 37: 882-90
29. Fraser AG, Sawyerr AM, Smith MS, et al. Morning versus evening dosing of lansoprazole 30 mg daily on twenty-four-hour intragastric acidity in healthy subjects. Aliment Pharmacol Ther 1996 Aug; 10 (4): 523-7
30. Fraser AG, Sawyerr AM, Hudson M, et al. Morning versus evening dosing of lansoprazole 30mg daily on twenty-four-hour intragastric acidity in healthy subjects. Aliment Pharmacol Ther 1996; 10: 523-7
31. Baldi F, Morselli-Labate AM, Cappiello R, et al. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis. Am J Gastroenterol 2002; 97: 1357-64
32. Shanley C, O'Loughlin G. Dysphagia among nursing home residents: an assessment and management protocol. J Gerontol Nurs 2000; 26: 35-48
33. Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 2000; 154: 150-4